Johnson & Johnson(JNJ -1.64%) announced priority review for its hepatitis C drug simeprevir. In this video, health-care analyst David Williamson discusses the positive aspects of this decision and how a competing drug also angling for approval may actually help boost sales for J&J.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Is Johnson & Johnson's simeprevir destined to be the first next-gen hepatitis-C drug.
David Williamson has no position in any stocks mentioned. Follow David on Twitter @MotleyDavid.
The Motley Fool recommends Gilead Sciences. It recommends and owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Johnson & Johnson
JNJ
$154.53
(-1.64%)
$-2.57
Gilead Sciences
GILD
$110.43
(0.41%)
$0.45
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?
These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025
Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.